- Open Access
Unrecognised cardiovascular disease in type 2 diabetes: is it time to act earlier?
Cardiovascular Diabetologyvolume 17, Article number: 145 (2018)
Cardiovascular disease (CVD) is the most significant prognostic factor in individuals with type 2 diabetes (T2D). However, a significant number of individuals may develop CVD that does not present with the classic angina-related or heart failure symptoms. In these cases, CVD may seem to be ‘silent’ or ‘asymptomatic’, but may be more accurately characterised as unrecognised diabetic cardiac impairment. An initial step to raise awareness of unrecognised CVD in individuals with T2D would be to reach a consensus regarding the terminology used to describe this phenomenon. By standardising the terminologies, and agreeing on the implementation of an efficient screening program, it is anticipated that patients will receive an earlier diagnosis and appropriate and timely treatment. Given the availability of anti-diabetic medications that have been shown to concomitantly reduce CV risk and mortality, it is imperative to improve early identification and initiate treatment as soon as possible in order to enable as many patients with T2D as possible to benefit.
Cardiovascular disease (CVD) has been shown to have a significantly high prevalence, incidence and mortality in individuals with type 2 diabetes (T2D). Moreover, patients with T2D may have seemingly asymptomatic CV damage [1, 2], with ischaemic episodes remaining undetected at a reported prevalence of one in three patients with diabetes (compared with one in five patients without diabetes) . Therefore, CV sequelae may develop much earlier than detected, with the disease only recognised once symptoms are more pronounced [2, 4]. At a regional expert meeting convened to consider the challenges presented by unrecognised CVD in T2D, we identified a lack of clarity with regard to definitions, diagnostic criteria, prevalence and care. The atypical symptoms of CVD experienced by patients with T2D have variously been described as ‘silent’ or ‘asymptomatic’. Without a clear terminology, and with a paucity of recent studies, an assessment of prevalence is challenging, while guidelines have to rely on data obtained without uniform definitions and before the development of current standards of care. In light of this, we would like to propose a definition for unrecognised CVD in patients with T2D, as an initial step towards providing clarity on the disease, the atypical symptoms that healthcare professionals should be aware of, and how best to assess patients for unrecognised CVD. We also seek to offer a vision for how an improved definition could ultimately lead to a simple and readily implementable screening strategy.
T2D as a risk factor for CVD
The association between CVD and T2D has long been established, with CVD remaining the principal cause of death and major source of disability among individuals with T2D, in part due to an exacerbation of mechanisms that underlie atherosclerosis and heart failure. Types of CVD with increased prevalence in patients with T2D include peripheral arterial disease, ischaemic stroke, stable angina, heart failure and non-fatal myocardial infarction . A recent meta-analysis of 43 studies found that diabetes was adversely associated with long-term survival and risk of hospitalisation in 380,000 patients with acute and chronic heart failure (the prevalence of diabetes in the cohort was 26%) .
There is also evidence to suggest that for a proportion of patients with T2D the occurrence of CVD may go unrecognised [1, 2]. Often, patients with T2D report only weakness and shortness of breath during exertion, which might in many cases mask significant CVD. So-called ‘silent’ myocardial infarction occurs in approximately 20% of patients with T2D , and is associated with a poor prognosis , while evidence of ‘silent’ ischaemia is seen in the electrocardiograms of 34% of patients with T2D, compared with only 19% of controls (p < 0.02) . Indeed, the atypical symptoms associated with unrecognised CVD can result in patients not receiving appropriate medical treatment that may be needed to prevent subsequent adverse outcomes, including those that occur from excessive physical effort.
The mechanisms that underlie the atypical nature of CVD symptoms in some patients with T2D require further investigation. Whereas ischaemia-related symptoms may result from classic vascular risk factors associated with T2D, atypical symptoms (Fig. 1a) may instead be due to impaired pain sensation  or other yet undefined mechanisms. Diabetic cardiac autonomic neuropathy (CAN), which may affect up to 34% of patients with T2D, may cause abnormalities in heart rate control and vascular dynamics that can result in exercise intolerance, orthostatic hypotension, asymptomatic ischaemia and painless myocardial infarction . CAN has been associated with increased prevalence of arrhythmia, sudden death and left ventricular diastolic dysfunction (LVDD) in patients with T2D; LVDD can progress to heart failure with preserved ejection fraction, with increased morbidity and mortality . A recent observational study in patients with T2D, in addition to at least one additional CV risk factor and LDL cholesterol < 3.35 mmol/L, found that silent myocardial ischaemia was associated with risk factors that included atherogenic dyslipidaemia (triglycerides ≥ 2.26 mmol/L and HDL cholesterol ≤ 0.88 mmol/L), peripheral occlusive arterial disease, retinopathy and male sex .
Current challenges in diagnosing and managing unrecognised CVD in T2D
At the present time, the phenomenon of unrecognised CVD in individuals with T2D is under-reported in the literature. There is a paucity of good quality, large-scale studies that fully explore the prevalence, incidence and prognostic potential of unrecognised CVD . What studies do exist predate the possibility to provide DES as an invasive intervention  and current optimised care based on an understanding of cardioprotective effects with certain antidiabetic therapies.
The quality of evidence upon which current recommendations for screening asymptomatic patients are based is therefore limited, both in the power of the studies considered and in predating the availability of newer, innovative anti-diabetic drugs that have been demonstrated to improve CV outcomes in patients with T2D and CVD. This is particularly pertinent given that American Diabetes Association (ADA) recommendations on screening asymptomatic patients  were based on the findings of clinical studies that did not include these therapies. The European Society of Cardiology (ESC)/European Association for the Study of Diabetes (EASD) 2013 Guidelines on diabetes, prediabetes and CVD advised screening in selected patients, but identified a need to better characterise which patient will benefit [2, 10]. Thus, readily implementable guidance on how best to screen for unrecognised CVD is also needed.
A recent regional meeting of experts from 15 countries in Central and Eastern Europe convened to discuss the problem of unrecognised CVD in patients with T2D. There was unanimous agreement among the experts present that the changing treatment landscape provides an impetus for reconsidering current screening guidelines, and that the failure of the ADA guidelines to recommend screening of so-called “asymptomatic patients” with high atherosclerotic CV disease risk should be re-examined (Fig. 1b). When considering approaches to screening, the majority of experts who were present agreed that CV risk calculation systems, such as the American College of Cardiology and American Heart Association Atherosclerotic CVD Risk Calculator, should form part of patient evaluations.
The meeting also identified an initial challenge in agreeing on standardised definitions and terminology to describe unrecognised CVD: terms such as ‘silent’ and ‘asymptomatic’ have been used interchangeably when discussing this phenomenon—neither of which may be an accurate description, as CVD can arguably never be truly asymptomatic. Instead, “unrecognised diabetic cardiac impairment (UDCI)” is proposed as a standardised terminology that accurately accounts for the phenomenon of ‘asymptomatic’ CVD that is unrecognised in patients with T2D.
By standardising the way in which unrecognised CVD is defined, discussed and described, it is hoped that awareness of this most important prognostic factor of T2D will be increased among both patients and healthcare professionals. A more consistent use of terminology in research will enable improved evaluation of the prevalence and manifestation of UDCI in patients with T2D. Such increased awareness should drive the development of tools that may be used for effective, non-invasive patient screening, concurrent with a re-examination of guidelines in order to acknowledge the need for such screening. In time, we envisage that screening of patients will become a more accepted and routine part of regular care, with earlier identification of CVD enabling more patients to benefit from early treatment, including with anti-diabetic therapies that offer a concomitant reduction in CV morbidity and mortality.
Arriving at a standardised terminology is only the first step in a complex set of challenges. It is vital that there is increased awareness of UDCI amongst both patients with T2D and the healthcare professionals managing their treatment. Additional clinical studies are required to examine the true prevalence of UDCI, and to define the key risk factors and atypical symptoms that characterise this phenomenon. As research progresses, best practice recommendations will need to be developed for identifying and managing UDCI. Importantly, optimal screening and treatment strategies should take into account key criteria such as cost effectiveness for healthcare systems and the availability of anti-diabetic treatments with a proven ability to reduce CV morbidity and mortality.
Defining unrecognised CVD in T2D
Given the variety of terms currently employed when discussing unrecognised CVD in T2D, it is unsurprising that this phenomenon is not widely recognised or appreciated. By establishing a consensus with regard to the terminology used, it should be possible to ensure that no pertinent data relating to this condition are overlooked owing to the use of an unfamiliar name. We would propose that ‘silent’ or ‘asymptomatic’ CVD in individuals with T2D should be referred to as ‘unrecognised diabetic cardiac impairment’ (UDCI), thereby highlighting the hidden nature of this condition, together with the link between atypical symptoms and diabetes (Fig. 1).
We acknowledge the importance of all types of unrecognised CV risk within the T2D patient population, including ischaemia and diastolic dysfunction (DD), which can lead to heart failure. Therefore, we propose that initial efforts to develop our understanding of UDCI should include, in addition to ischaemia, assessment of left ventricular dysfunction and/or heart failure (Fig. 1b). We expect that this pragmatic approach is most likely to yield success, for several reasons. First, there is a wide acceptance that heart failure is a major comorbidity associated with T2D. Second, there are a range of simple and cost-effective screening strategies and tools to investigate the risk of unrecognised heart failure as a component of UDCI among individuals with T2D. Third, SGLT2 inhibitors, a new class of anti-hyperglycaemic therapies, have shown promise in reducing the risk of hospitalisation for heart failure among patients with T2D, which has prompted ongoing clinical studies with pre-specified HF outcomes . This emerging evidence was recognised by the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (specifically, for empagliflozin based on the results of the EMPA-REG OUTCOME® trial) , and suggests the potential for a positive effect on healthcare spending with appropriate early detection and treatment of conditions with a high risk for developing heart failure.
A relevant consideration for heart failure is that its prevalence is particularly high in elderly patients, and that the number of elderly patients with diabetes is increasing. We note that subgroup analyses of clinical studies have suggested that the potential of SGLT2 inhibitors to improve HF outcomes is retained even when looking only at this older population.
Screening for UDCI
The existence of a clearly defined, widely accepted, standard terminology for UDCI should provide consensus within the medical community regarding when and how healthcare professionals should screen patients with T2D for CV risk. Standardisation of terminologies would provide clarity around this point and allow for the implementation of simple, readily available screening options that fulfil the following key criteria by being: cost effective; widely available; simple to administer and understand; capable of providing immediate patient feedback in order to facilitate more rapid decision making; and scope to permit the stratification of patients (Fig. 1b). A variety of tools are available that meet these criteria; these include the use of questionnaires to obtain detailed patient histories, digital data gathering using wearable personal health trackers, the stress test or 6-min walking test and the use of biomarkers such as B-type natriuretic peptide (BNP) or N-terminal pro BNP (Table 1). An echocardiogram may also be appropriate in suspected cases.
Unrecognised CVD presents a significant burden in patients with T2D, and it is imperative that we improve the early identification and treatment of this vulnerable patient population. At the present time, a lack of clarity in terms of how unrecognised CVD is defined, diagnosed and treated, together with a paucity of relevant guideline recommendations, mean that patients may often be under-treated. We propose the introduction of UDCI as a standardised terminology, and call for a concerted effort to increase awareness of this condition and its consequences. By so doing, it should be possible to define the correct screening programme to facilitate early and appropriate treatment of patients with T2D and to minimise adverse CV outcomes.
American Diabetes Association
B-type natriuretic peptide
cardiac autonomic neuropathy
European Society of Cardiology
type 2 diabetes
unrecognised diabetic cardiac impairment
Ditchburn CJ, Hall JA, de Belder M, Davies A, Kelly W, Bilous R. Silent myocardial ischaemia in patients with proved coronary artery disease: a comparison of diabetic and non-diabetic patients. Postgrad Med J. 2001;77:395–8.
Makrilakis K, Liatis S. Cardiovascular Screening for the Asymptomatic Patient with Diabetes: more Cons Than Pros. J Diabetes Res. 2017;2017:8927473.
Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation. 2003;108(10):1263–77.
Davis TM, Coleman RL, Holman RR, Group U. Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. Circulation. 2013;127:980–7.
Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, Deanfield J, Smeeth L, Timmis A, Hemingway H. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol. 2015;3:105–13.
Dauriz M, Mantovani A, Bonapace S, Verlato G, Zoppini G, Bonora E, Targher G. Prognostic impact of diabetes on long-term survival outcomes in patients with heart failure: a meta-analysis. Diabetes Care. 2017;40:1597–605.
Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4–18.
Valensi P, Avignon A, Sultan A, Chanu B, Nguyen MT, Cosson E. Atherogenic dyslipidemia and risk of silent coronary artery disease in asymptomatic patients with type 2 diabetes: a cross-sectional study. Cardiovasc Diabetol. 2016;15:104.
American Diabetes A. Improving care and promoting health in populations: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S7–12.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129–200.
All authors participated in the discussion during the face-to-face meeting, with GS and CL moderating the conversation. All authors contributed to the content and critical review of the manuscript. All authors read and approved the final manuscript.
Editorial support was provided by Fortis Pharma Communications, with financial support by Boehringer Ingelheim (BI). The opinions expressed are entirely the authors’ own and the only involvement of BI was to have sight of the manuscript for accuracy.
(1)GS has previously received research grants and honoraria for speaking from Abbot, Amgen, Andromeda, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, DeveloGen, Eli Lilly, GSK, Janssen, Merck, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Serono, Servier and Takeda, and has served as principal investigator in more than 40 studies. (2) CL has previously received honoraria for speaking and consultancy from AstraZeneca, Bendit, Boehringer Ingelheim, Boston Scientific, Cordio, CardiaX, Healthwatch, Medtronic and MSD. (3) ET has previously received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Gedeon Richter, Merck Bulgaria, Pfizer and Sanofi. (4) JC has previously received honoraria for speaking from AstraZeneca, Boehringer Ingelheim and Novo Nordisk. (5) MC has no competing interests. (6) KD has previously received honoraria for speaking from AstraZeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly, GSK, Merck Serono, MSD, Novartis, Novo Nordisk, Sanofi, Servier and Takeda. (7) EG has previously received honoraria for consultation and speaking from Actelion, Boehringer Ingelheim, Novartis and Servier. (8) CJ has participated in scientific advisory boards and received consultancy/lecturing fees from AstraZeneca, Bayer AG, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi. (9) MH has previously participated in advisory boards and received speakers honoraria from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Sanofi. (10) AJ has previously received honoraria from Amgen, AstraZeneca, Boehringer Ingelheim, Medtronic, Merck, MSD, Novo Nordisk, Sanofi. (11) NL has no competing interests. (12) RL has previously received honoraria for speaking and consultancy from AstraZeneca, Boehringer Ingelheim, EliLilly, Medtronic, MSD, Novo Nordisk, Sanofi and Roche. (13) NN has no competing interests. (14) PP has previously received honoraria for speaking and consultancy from Boehringer Ingelheim and Novo Nordisk. (15) AR has previously received honoraria for speaking and consultancy from Boehringer Ingelheim. (16) IS has previously received honoraria for consultancy and funding for studies from Abbott, AstraZeneca, Boehringer Ingelheim, Gedeon Richter, KRKA, MSD, Pfizer, Recordati and Teva. (17) LSD has previously received honoraria for speaking and consultancy from Abbott, Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Merck, MSD, Novo Nordisk, Sanofi, Servier and Takeda.
Availability of data and material
All data generated or analysed during this study are included in this published article.
Consent for publication
Ethics approval and consent to participate
Organisation of the meeting and editorial support was provided by Boehringer Ingelheim with the support of the medical communication agency Fortis Pharma Communications.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.